KAPA (Kairos Pharma) 3-Month Share Buyback Ratio: -2.83% (As of Mar. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAPA Kairos Pharma Ltd KAPA
15 GF Score
Price $0.39
View Full Analysis

What is Kairos Pharma 3-Month Share Buyback Ratio?

Kairos Pharma KAPA -1.03% 15 3-Month Share Buyback Ratio is -2.83 as of Mar. 2026. GuruFocus rates KAPA with a GF Score™ of 15/100.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Kairos Pharma's current 3-Month Share Buyback Ratio was -2.83%.

Kairos Pharma  (AMEX:KAPA) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Kairos Pharma 3-Month Share Buyback Ratio Related Terms

KAPA vs ACXP, PULM, ADIL: 3-Month Share Buyback Ratio Comparison

For the Biotechnology subindustry, Kairos Pharma's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kairos Pharma 3-Month Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kairos Pharma's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Kairos Pharma's 3-Month Share Buyback Ratio falls into.


KAPA
15GF Score
Kairos Pharma Ltd KAPA
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kairos Pharma 3-Month Share Buyback Ratio Calculation

Kairos Pharma's 3-Month Share Buyback Ratio for the quarter that ended in Mar. 2026 is calculated as

3-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Dec. 2025 ) - Shares Outstanding (EOP) (Mar. 2026 )) / Shares Outstanding (EOP) (Dec. 2025 )
=(20.821 - 21.411) / 20.821
=-2.83%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 3-Month Share Buyback Ratio of -2.83 mean?
Kairos Pharma (KAPA) has a 3-Month Share Buyback Ratio of -2.83 as of Mar. 2026. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Kairos Pharma and its competitors.
Is Kairos Pharma's 3-Month Share Buyback Ratio too high?
Kairos Pharma's current 3-Month Share Buyback Ratio is -2.83. Overall, Kairos Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Kairos Pharma's 3-Month Share Buyback Ratio compare to ACXP and PULM?
Kairos Pharma's 3-Month Share Buyback Ratio of -2.83 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Biotechnology company?
A good 3-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Kairos Pharma and its competitors. Kairos Pharma's current 3-Month Share Buyback Ratio is -2.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kairos Pharma stock overvalued right now?
Kairos Pharma (KAPA) has a current 3-Month Share Buyback Ratio of -2.83. The current 3-Month Share Buyback Ratio is -2.83. Kairos Pharma's overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Kairos Pharma (KAPA), the current 3-Month Share Buyback Ratio is -2.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kairos Pharma Business Description

Address 2355 Westwood Boulevard, No. 139, Los Angeles, CA, USA, 90064
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
15GF Score

Get the complete analysis for KAPA

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.39
Price